STIM
Neuronetics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About STIM
Neuronetics, Inc.
A commercial stage medical technology company focused on products for neurohealth disorders
Healthcare Equipment and Supplies
--
06/28/2018
NASDAQ Stock Exchange
716
12-31
Common stock
3222 Phoenixville Pike, Malvern, Pennsylvania , 19355
--
Neuronetics, Inc., was incorporated in Delaware in April 2003. The company is a commercial stage medical technology company focused on designing, developing and selling products that improve the quality of life of people with mental illness. The company's first commercial product, the NeuroStar Advanced Treatment System, is a non-invasive, non-systematic, office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with emotion. The U.S. Food and Drug Administration, or FDA, approved the system to treat adult patients with major depression or MDD who have not achieved satisfactory improvement from previous antidepressants in their current MDD episodes.
Earnings Call
Q1/2025
Estimate EPS-0.12
Actual EPS-0.21
Estimate Revenue29.07M
Actual Revenue32.00M
Neuronetics Q1 2025: Unraveling Contradictions in Growth Drivers, Merger Insights, and Financial Expectations
May 06,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.08
Actual EPS-0.15
Estimate Revenue36.94M
Actual Revenue38.11M
Neuronetics Q2 2025: Navigating Contradictions in Marketing Strategies and Revenue Expectations
Aug 05,2025 01:05
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.12
Actual EPS-0.13
Estimate Revenue37.85M
Actual Revenue21.80M
Neuronetics' Q3 2025: Contradictions Emerge on Greenbrook/NeuroStar Revenue Dynamics, Gross Margins, and Utilization Growth
Nov 04,2025 12:40
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
STIM has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.12, missing expectations. The chart below visualizes how STIM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
STIM has released its 2025 Q3 earnings report, with revenue of 37.30M, reflecting a YoY change of 101.28%, and net profit of -9.40M, showing a YoY change of 29.53%. The Sankey diagram below clearly presents STIM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
